Some push for FDA approval of psychedelic treatments for veterans

Published: Friday, December 5, 2025 at 8:28 pm

Psychedelic Treatment for Veterans Gains Momentum, Faces Regulatory Hurdles

A growing movement is advocating for the U.S. Food and Drug Administration (FDA) to approve ibogaine, a compound derived from the African shrub iboga, for therapeutic use, particularly for veterans suffering from post-traumatic stress (PTS). Proponents highlight the potential of ibogaine to alleviate symptoms of depression, anxiety, and improve overall functioning, citing a 2024 Stanford Medicine study that supports these claims.

The push for FDA approval is gaining traction, with several states expressing interest in funding research and clinical trials. Texas has already committed $50 million to this cause, and other states, including Alabama, Idaho, South Carolina, Kentucky, Maryland, Mississippi, Tennessee, New Hampshire, Oklahoma, and Vermont, are considering similar initiatives.

However, the path to approval is not without obstacles. Ibogaine is currently classified as a Schedule I drug in the United States, meaning it has no currently accepted medical use and a high potential for abuse. Concerns about safety have also been raised, with some medical professionals expressing reservations about the drug's potential for FDA approval.

Despite these challenges, support for exploring psychedelic treatments is evident at the federal level. FDA Commissioner Marty Makary and U.S. Department of Health and Human Services Secretary Robert F. Kennedy Jr. have signaled interest in investigating these options.

BNN's Perspective:

The potential of ibogaine to provide relief for veterans struggling with PTS is a compelling argument. While the anecdotal evidence and initial studies are promising, it is crucial to proceed cautiously. Rigorous clinical trials and thorough safety assessments are essential before widespread use is considered. The FDA must balance the potential benefits with the need to protect patients from potential risks. A measured approach, prioritizing scientific evidence and patient safety, is the most responsible path forward.

Keywords: ibogaine, psychedelic, veterans, PTSD, FDA, clinical trials, mental health, depression, anxiety, treatment, drug approval, Texas, Kentucky, Stanford Medicine, Schedule I drug

Full Story